Chonluten vs Thymosin Alpha-1

Tripeptide bioregulator targeting bronchial epithelial cells; normalizes gene expression in bronchial tissue; promotes epithelial regeneration

Chonluten is a synthetic tripeptide (Glu-Asp-Gly, EDG) classified as a Khavinson-class bioregulator peptide targeted at bronchial and lung epithelial tissue, investigated for cytoprotective and anti-aging properties in the respiratory epithelium through proposed gene expression regulatory mechanisms. Like other short Khavinson bioregulator peptides, chonluten is proposed to reach target bronchial cells via proton-coupled oligopeptide transporter (POT) and large amino acid transporter (LAT) uptake mechanisms, and to modulate transcriptional activity in aging or injured lung tissue. Published research on Khavinson-class ultrashort peptides has characterized intracellular transport mechanisms via POT and LAT carriers and demonstrated gene expression regulation by short peptides across multiple tissue types, providing the mechanistic framework within which chonluten's bronchial effects are proposed. Chonluten has no FDA approval or regulatory approval in any major jurisdiction outside Russia; evidence derives from Khavinson-series preclinical and class-level studies with no independent clinical trials published in Western-indexed journals. Chonluten vs cerluten: lung vs bronchial specificity Chonluten is a Khavinson-class short bioregulator peptide proposed to target lung parenchymal tissue rather than the bronchial epithelium (cerluten's proposed target). In the Khavinson organ-specific bioregulator model, different tripeptide or tetrapeptide sequences are proposed to reach distinct tissue types via amino acid transporters and modulate gene expression selectively in those tissues. Chonluten's research applications focus on age-related pulmonary function decline, oxidative stress in lung tissue, and support of alveolar cell function — complementary to but distinct from bronchial applications. Research context for chonluten, like other Khavinson class peptides, comes primarily from the Khavinson Institute (St. Petersburg) preclinical aging models and observational clinical data from Eastern European medical settings; independent large-scale RCT evidence is absent. Standard Khavinson protocol cycles apply: oral capsule, 10–20 day cycles, rest intervals. Chonluten is available from specialty Eastern European suppliers and Russian pharmacy channels; it is not an approved pharmaceutical in Western regulatory jurisdictions. It is sometimes stacked with cerluten in protocols targeting comprehensive respiratory tissue support, though no clinical evidence for this combination exists.

Tα1 modulates both innate and adaptive immune responses by stimulating the differentiation and maturation of T-cells, dendritic cells, and natural killer cells. It upregulates MHC class I and II expression, enhancing antigen presentation. It also promotes the production of key cytokines including interferon-γ and interleukin-2, which are central to immune surveillance.

Thymosin alpha-1 (thymalfasin; Zadaxin) is a 28-amino-acid synthetic peptide corresponding to the N-terminal sequence of prothymosin alpha, developed as a biological response modifier with established clinical use outside the United States for chronic viral hepatitis and as an immune adjuvant in cancer and immunocompromised patients. Thymalfasin modulates innate and adaptive immune responses by upregulating Toll-like receptor expression and dendritic cell maturation, enhancing T-helper 1 cytokine signaling, and potentiating antigen-specific T-cell responses in settings of impaired immune function. A prospective multicenter randomized controlled trial demonstrated that combination therapy with thymosin alpha-1 and entecavir improved serological outcomes in HBV-related compensated cirrhosis compared to entecavir alone, and cumulative RCT evidence supports its role as an immune adjuvant in hepatitis B and C treatment. Thymosin alpha-1 is approved in approximately 35 countries — including China, Italy, and other Asian and Eastern European markets — for hepatitis B and hepatitis C adjuvant therapy, but has not received FDA approval in the United States and is available in US-adjacent research contexts only as an investigational compound. Thymosin alpha-1 dosage: in approved clinical protocols (hepatitis B adjuvant therapy), thymalfasin is administered as 1.6 mg subcutaneously twice weekly for 26–52 weeks. This dosing schedule is derived from the pivotal trials conducted by SciClone Pharmaceuticals, which developed Zadaxin. In COVID-19 research during 2020–2021, Chinese clinical centers studied thymosin alpha-1 as an immune adjuvant in severe and critical COVID-19 patients, with published observational and small RCT data; this research context brought renewed attention to the peptide's immune-modulating properties outside the hepatitis indication. Within the recovery and immune-support peptide landscape, thymosin alpha-1 is most closely compared to thymosin beta-4 (TB-500) — the two peptides share the thymosin nomenclature but have distinct mechanisms and research profiles. Thymosin alpha-1 is an immune activator (TH1 upregulation); thymosin beta-4 is primarily studied for tissue repair and actin dynamics. Providers offering immune-modulating peptide compounds are listed in the PeptideBase directory.